Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
GoldInxs Mining Corp. Closes Initial Public Offering and Announces Listing on the TSX Venture Exchange
Ni-Co Énergie annonce des résultats d'échantillons choisis à Kremer-2 titrant jusqu'à 1,21 % Ni, 0,14 % Cu et 0,10 % Co; 11 des 33 échantillons de Kremer-2 ont retourné plus de 0,5 % Ni.
Ni-Co Energy Announces Kremer-2 Grab Sample Results Grading Up to 1.21% Ni, 0.14% Cu and 0.10% Co; 11 of 33 Kremer-2 Samples Returned More Than 0.5% Ni.
